Andrea C. Gore, PhD, of the University of Texas in Austin, discusses her recent Journal of the Endocrine Society paper, which found that early-life exposure to a class of endocrine-disrupting chemicals called polychlorinated biphenyls – banned for decades but persistent in the environment — may lead to behavioral problems later in life. Late last year,...
Recently I was watching a couple of movies from the 1970s; one was a drama filmed in New York City and the other was a documentary filmed in California. There were plenty of random shots of people in streets as well as crowds at various events throughout both. However, one thing about both movies that...
A third generation of the latest cholesterol-lowering medication — PCSK9-inhibitors — will soon be available for patients with homozygous familial hypercholesterolemia (HoFH), according to a January 24 article in The Lancet Diabetes & Endocrinology. Affecting approximately 30,000 individuals worldwide, HoFH is a rare but serious genetic disorder in which patients have markedly elevated levels (>10...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized weight loss management, and researchers are now exploring how these medications can further transform obesity care and offer new possibilities for long-term weight management, according to a recent review article published in Endocrinology. Authors Lauren A. Jones and Daniel I. Brierley, PhD, both of the Centre for Cardiovascular...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Celltrion Receives U.S. FDA Approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Biosimilars Referencing PROLIA® and XGEVA® On March 3, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively...
Fatima Cody Stanford, MD, MPH, MPA, MBA, takes the lessons she learned growing up in Atlanta serving her community and applies them to her work treating obesity. In July, she’ll give the plenary presentation at ENDO 2025, “Changing the Game of Obesity Care Across Lifespan: Policies, Diets, and Drug Innovation,” offering attendees a comprehensive overview...
Priyanka Majety, MD, discusses a new, FDA-approved wearable insulin-delivery patch that could potentially improve patients’ insulin adherence as well as their quality of life. Last summer, a wearable patch designed for mealtime insulin delivery (in lieu of traditional injections) received clearance from the U.S. Food and Drug Administration, extending the patch’s wear time from three...
The Society for Women’s Health Research (SWHR) will honor Teresa Woodruff, PhD, with a Women’s Health Visionary Award for her contributions to women’s health research in endocrinology, ovarian biology, and reproductive science during its 35th Annual Awards Gala. Woodruff is also being honored for her leadership surrounding the sex as a biological variable policy within the...
Andrea C. Gore, PhD, of the University of Texas in Austin, discusses her recent Journal of the Endocrine Society paper, which found that early-life exposure to a class of endocrine-disrupting chemicals called polychlorinated biphenyls – banned for decades but persistent in the environment — may lead to behavioral problems later in life. Late last year,...
Recently I was watching a couple of movies from the 1970s; one was a drama filmed in New York City and the other was a documentary filmed in California. There were plenty of random shots of people in streets as well as crowds at various events throughout both. However, one thing about both movies that...
The Society for Women’s Health Research (SWHR) will honor Teresa Woodruff, PhD, with a Women’s Health Visionary Award for her contributions to women’s health research in endocrinology, ovarian biology, and reproductive science during its 35th Annual Awards Gala. Woodruff is also being honored for her leadership surrounding the sex as a biological variable policy within the...